Literature DB >> 2823254

Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence.

C E Rubens1, M R Wessels, L M Heggen, D L Kasper.   

Abstract

The capsular polysaccharide of type III group B Streptococcus (GBS) is thought to be a major factor in the virulence of this organism. Transposon mutagenesis was used to obtain isogenic strains of a GBS serotype III clinical isolate (COH 31r/s) with site-specific mutations in the gene(s) responsible for capsule production. The self-conjugative transposon Tn916 was transferred to strain COH 31r/s during incubation with Streptococcus faecalis strain CG110 on membrane filters. Eleven transconjugant clones did not bind type III GBS antiserum by immunoblot. Immunofluorescence, competitive ELISA, and electron microscopy confirmed the absence of detectable GBS type III capsular polysaccharide in one of the transconjugants, COH 31-15. Southern hybridization analysis with a Tn916 probe confirmed the presence of the transposon sequence within each mutant. A 3.0-kilobase EcoRI fragment that flanked the Tn916 sequence was subcloned from mutant COH 31-15. This fragment shared homology with DNA from the other GBS serotypes, suggesting a common sequence for capsulation shared by organisms of different capsular types. Loss of capsule expression resulted in loss of virulence in a neonatal rat model. We conclude that a gene common to all capsular types of GBS is required for surface expression of the type III capsule and that inactivation of this gene by Tn916 results in the loss of virulence.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2823254      PMCID: PMC299259          DOI: 10.1073/pnas.84.20.7208

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Bacterial capsule--old dogmas and new tricks.

Authors:  D L Kasper
Journal:  J Infect Dis       Date:  1986-03       Impact factor: 5.226

2.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

3.  Electron microscopic definition of surface antigens of group B Streptococcus.

Authors:  D L Kasper; C J Baker
Journal:  J Infect Dis       Date:  1979-02       Impact factor: 5.226

4.  Opsonic specificity of human antibody to the type III polysaccharide of group B Streptococcus.

Authors:  M S Edwards; C J Baker; D L Kasper
Journal:  J Infect Dis       Date:  1979-12       Impact factor: 5.226

Review 5.  Group B streptococcal infections.

Authors:  C J Baker
Journal:  Adv Intern Med       Date:  1980

6.  Standardization and evaluation of the CAMP reaction for the prompt, presumptive identification of Streptococcus agalactiae (Lancefield group B) in clinical material.

Authors:  C L Darling
Journal:  J Clin Microbiol       Date:  1975-02       Impact factor: 5.948

7.  Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci.

Authors:  R S Baltimore; D L Kasper; C J Baker; D K Goroff
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

8.  ELISA methodology for polysaccharide antigens: protein coupling of polysaccharides for adsorption to plastic tubes.

Authors:  B M Gray
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

9.  Mouse protection test for group B Streptococcus type III.

Authors:  R S Baltimore; D L Kasper; J Vecchitto
Journal:  J Infect Dis       Date:  1979-07       Impact factor: 5.226

10.  Immunodeterminant specificity of human immunity to type III group B streptococcus.

Authors:  D L Kasper; C J Baker; R S Baltimore; J H Crabb; G Schiffman; H J Jennings
Journal:  J Exp Med       Date:  1979-02-01       Impact factor: 14.307

View more
  106 in total

1.  The Delta subunit of RNA polymerase is required for virulence of Streptococcus agalactiae.

Authors:  Amanda L Jones; Rachel H V Needham; Craig E Rubens
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

2.  Influence of serotype of group B streptococci on C3 degradation.

Authors:  J R Campbell; C J Baker; M S Edwards
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

3.  Respiratory epithelial cell invasion by group B streptococci.

Authors:  C E Rubens; S Smith; M Hulse; E Y Chi; G van Belle
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

4.  Deposition and degradation of C3 on type III group B streptococci.

Authors:  J R Campbell; C J Baker; M S Edwards
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

5.  Modification of the CpsA protein reveals a role in alteration of the Streptococcus agalactiae cell envelope.

Authors:  Hannah M Rowe; Brett R Hanson; Donna L Runft; Qian Lin; Steve M Firestine; Melody N Neely
Journal:  Infect Immun       Date:  2015-02-02       Impact factor: 3.441

6.  Functional analysis of the CpsA protein of Streptococcus agalactiae.

Authors:  Brett R Hanson; Donna L Runft; Cale Streeter; Abhin Kumar; Thomas W Carion; Melody N Neely
Journal:  J Bacteriol       Date:  2012-01-27       Impact factor: 3.490

Review 7.  Interaction of neonatal phagocytes with group B streptococcus: recognition and response.

Authors:  Philipp Henneke; Reinhard Berner
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

8.  Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule.

Authors:  M R Wessels; C E Rubens; V J Benedí; D L Kasper
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

9.  Estimation of group B streptococcus type III polysaccharide-specific antibody concentrations in human sera is antigen dependent.

Authors:  R Bhushan; B F Anthony; C E Frasch
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

10.  Population structure of Streptococcus agalactiae reveals an association between specific evolutionary lineages and putative virulence factors but not disease.

Authors:  M Hauge; C Jespersgaard; K Poulsen; M Kilian
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.